BPC-157 vs Larazotide
Both BPC-157 and Larazotide are used for gut-health. Here's how their evidence, dosing, and regulatory status actually compare.
BPC-157
Evidence B+Body Protection Compound-157
A 15-amino-acid peptide derived from gastric juice. The most popular recovery peptide with 100+ preclinical studies showing accelerated healing of tendons, ligaments, muscle, gut lining, and nerves.
View full BPC-157 profile →Larazotide
Evidence B+Larazotide Acetate (AT-1001)
An 8-amino-acid oral peptide that tightens intestinal tight junctions by antagonizing zonulin signaling. The most-studied 'leaky gut' peptide with celiac trial data.
View full Larazotide profile →Side-by-Side
| Attribute | BPC-157 | Larazotide |
|---|---|---|
| Evidence Grade | B+ | B+ |
| FDA Status | Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026) | Not FDA-approved — Phase 3 completed for celiac disease (results mixed) |
| Typical Dose | 250–500 mcg twice daily (subcutaneous) | 0.5 mg three times daily before meals (oral) |
| Clinics Indexed | 308 | 33 |
| Categories | recovery, gut-health | gut-health |
Key reported benefits — BPC-157
- ✓Tendon & ligament repair
- ✓Gut healing
- ✓Muscle recovery
- ✓Neuroprotection
Key reported benefits — Larazotide
- ✓Tight-junction restoration
- ✓Intestinal permeability reduction
- ✓Celiac symptom reduction
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.